Completed PHASE1/PHASE2 INTERVENTIONAL NCT01534585

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Phase Ⅰ/Ⅱ Study of Icotinib Hydrochloride Combined With Intensity-modulated Radiotherapy in Nasopharyngeal Cancer

Sponsor: Taizhou Hospital

Interventions Epidermal growth factor receptor status Icotinib Paclitaxel and Cisplatin Quality of life intensity-modulated radiotherapy

Updated 6 times since 2017 Last updated: Apr 16, 2018 Started: Feb 29, 2012 Primary completion: Feb 28, 2013 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Nasopharyngeal Carcinoma, this trial is completed. The trial is conducted by Taizhou Hospital and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — May 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taizhou Hospital

Data source: Taizhou Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taizhou, China